Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment

Journal of Hypertension

Volumn 31, Issue 8, 2013, Pages 1683-1691

  Rodilla, Enrique ^a,b   Pascual, Jose Maria ^a,b   Costa, Jose Antonio ^a,b   Martin, Joaquin ^a   Gonzalez, Carmen ^a   Redon, Josep ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

left ventricular hypertrophy; left ventricular hypertrophy regression; microalbuminuria; microalbuminuria regression

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXCRETION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; OUTPATIENT CARE; PRIORITY JOURNAL; PROBABILITY; SMOKING; TWO DIMENSIONAL ECHOCARDIOGRAPHY; WAIST CIRCUMFERENCE;

EID: 84880523770     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328361461e     Document Type: Article

References (29)

1. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
2. Guidelines Committee. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
3. Facila L, Bertomeu V, Bertomeu-Gonzalez V, Morillas P, Mazon P, Gonzalez-Juanatey JR, VIIDA study. Association between renal function and cardiovascular disease in patients with left ventricular hypertrophy. VIIDA Study. J Clin Hypertens 2009; 11:303-308.
4. Redon J, Baldó E, Lurbe E, Bertolin V, Lozano JV, Miralles A, et al. Microalbuminuria, left ventricular mass and ambulatory blood pressure in essential hypertension. Kidney Int 1996; 49 (Suppl 55):S81-S84.
5. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143:319-326.
6. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356.
7. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16:895-899.
8. Mann JF, Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.
9. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, et al. ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22:1353-1364.
10. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlof B, Devereux RB, et al., LIFE Study Investigators. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24:775-781.
11. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39:794-798.
12. Pascual JM, Rodilla E, Gonzalez C, Perez-Hoyos S, Redon J. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 2005; 45:1132-1137.
13. Pascual JM, Rodilla E, Miralles A, Gonzalez C, Redon J. Determinants of urinary albumin excretion reduction in essential hypertension: a longterm follow-up study. J Hypertens 2006; 24:2277-2284.
14. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
16. Devereaux RB, Reickeck N. Echocardiographic determination of left ventricular mass in man. Anatomical validation of the method. Circulation 1977; 55:613-618.
17. Palmieri V, Dahlof B, DeQuattro V, Sharpe N, Bella J, de Simone G, et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE Study. J Am Coll Cardiol 1999; 34:1625-1632.
18. Viazzi F, Parodi D, Leoncini G, Vettoretti S, Ratto E, Vaccaro V, et al. Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 2004; 22:907-913.
19. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, et al. Which markers of subclinical organ damage to measure in individuals with high normal blood pressure? J Hypertens 2009; 27:1165-1171.
20. Assadi F. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol 2007; 1:27-33.
21. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
22. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29:595-600.
23. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 2004; 18:453-459.
24. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54:1084-1091.
25. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13:564-569.
26. Gerdts E, Roman MJ, Palmieri V, Wachtell K, Smith G, Nieminen MS, et al. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). J Hum Hypertens 2004; 18:417-422.
27. Okin PM, Gerdts E, Kjeldsen SE, Julius S, Edelman JM, Dahlof B, Devereux RB, Losartan Intervention for Endpoint Reduction in Hypertension Study Investigators. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy. Hypertension 2008; 52:100-106.
28. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al., Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464-1470.
29. Cuspidi C, Esposito A, Negri F, Sala C, Masaidi M, Giudici V, et al. Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am J Hypertens 2008; 21:458-463.